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Abstract.  The interactions between exogenously added 
tissue-type plasminogen activator (t-PA) and the active 
form of type 1 plasminogen activator inhibitor (PAl-l) 
produced by and present in cultured human umbilical 
vein endothelial cells (HUVECs)  were investigated. 
Immunoblotting analysis of the conditioned media ob- 
tained from monolayers of HUVECs treated with in- 
creasing concentrations of t-PA (~<10/zg/ml) revealed a 
dose-dependent formation of both t-PA/PAI-1  com- 
plexes, and of a 42,000-M, cleaved or modified form 
of the inhibitor. Immunoradiometric assays indicated 
that t-PA treatment resulted in a  fourfold increase in 
PAI-1 antigen present in the conditioned media. This 
increase did not result from the release of PAI-1 from 
intracellular stores, but rather reflected a t-PA- 
dependent decrease in the PAI-1 content of the Triton 
X-100  insoluble extracellular matrix (ECM).  Although 
the rate of t-PA-mediated release of PAI-1 was in- 
creased by the removal of the monolayer, similar quan- 
tities of PAI-I  were removed in the presence or ab- 
sence of the cells. These results suggest that the cells 
only represent a  semipermeable barrier between ECM- 
associated PAI-1 and exogenous t-PA. Treatment of 
HUVECs with t-PA (1  /xg/ml, 2  h) to deplete the 
ECM of PAI-1 did not affect the subsequent rate of 
PAI-1 production and deposition into the ECM.  Im- 
munogold electron microscopy of HUVECs not only 
confirmed the location of PAI-1 primarily in the region 
between the culture substratum and the ventral cell 
surface but failed to demonstrate significant (<1%) 
PAI-1 on the cell surface. Thus, the majority of PAId 
associated with cultured HUVEC monolayers is pres- 
ent under the cells in the ECM and is accessible to 
solution-phase t-PA. 
p 
LASMINOGEN activators (PAs)  ~  play an important role 
not only during fibrinolysis but also in a variety of 
other  physiological processes,  including tissue  re- 
pair, macrophage function, ovulation, embryo implantation, 
neovascularization, and malignant transformation (Astrup, 
1975; Reich, 1978; Bachmann and Kruithof, 1984). Precise 
regulation of PA activity thus constitutes a critical feature of 
many biological systems. Such control may be at the level of 
the formation and resolution of fibrin itself (Hoylaerts et al., 
1982), at the level of the interactions of PAs with cells (Vas- 
salli et al., 1985), or through the action of specific PA inhibi- 
tors (PAIs; Erickson et al., 1985; Sprengers and Kluft, 1987; 
Loskutoff et al.,  1988). 
Although four molecules with PAI activity have been de- 
tected, the endothelial cell-derived inhibitor (PAI-1) (Spren- 
gers and Kluft, 1987; Loskutoff  et al.,  1988) appears to be 
1. Abbreviations used in this paper: CM, conditioned medium; ECM, ex- 
tracellular matrix;  IRMA,  immunoradiometric assay;  HUVECs,  human 
umbilical vein endothelial cells; PA, plasminogen activator; PAl, plasmino- 
gen activator inhibitor; PAId, type 1 plasminogen activator inhibitor; t-PA, 
tissue-type plasminogen activator. 
the physiologic inhibitor of tissue-type plasminogen inhibi- 
tor (t-PA). PAI-I is a member of the serine proteinase inhibi- 
tor (Serpin) superfamily (Carrel and Travis,  1985; Ny et al., 
1986, Pannekoek et al.,  1986) and differs from other PAls 
in its stability to SDS (van Mourik et al., 1984; Hekman and 
Loskutoff,  1985),  its  electrophoretic  mobility  (Erickson 
et  al.,  1986),  and  its  ability to  inhibit single-chain t-PA 
(Colucci et al., 1986; Hekman and Loskutoff, 1988). In ad- 
dition, PAI-1 is synthesized as an active molecule but is un- 
stable in solution and rapidly decays into a latent, inactive 
form at 37°C  (Levin,  1986;  Kooistra et al.,  1986).  Active 
PAI-1 appears to be stabilized through its binding to other 
proteins (Loskutoff et al.,  1988).  For example,  PAI-1 has 
been detected in the extracellular matrix (ECM) of a variety 
of  cultured cells (Laiho et al., 1986; Levin and Santell, 1987; 
Knudsen et al., 1987; Mimuro et al., 1987; Rheinwald et al., 
1987; Pollanen et al.,  1987; Knudsen and Nachman,  1988) 
and shown to be active (Levin and Santell, 1987; Mimuro et 
al.,  1987, Knudsen and Nachman,  1988).  The binding of 
PAI-1 to the ECM protects it from the spontaneous inactiva- 
tion that occurs in solution, increasing its apparent half-life 
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protein in the ECM may be vitronectin (Mimuro and Losku- 
toff, 1989a,b). Active PAId in plasma is also detected in a 
complex with another molecule (Wiman et al., 1988) shown 
to be vitronectin (DeClerk et al.,  1988). 
The observation that t-PA is able to bind to and form com- 
plexes with the PAL1 associated with confluent human um- 
bilical vein endothelial cells (HUVECs) has led to the con- 
cept that active PAI-1 is also present on the surface of these 
cells (Barnathan et al., 1988; Sakata et al., 1988). However, 
accurate interpretation of these results may be hindered by 
the large amounts of PAId present in the ECM of these cells, 
especially if it is accessible to t-PA.  In this report, we have 
studied the interaction between exogenous t-PA and the PAL1 
associated with intact cultured HUVECs. We show that the 
majority of this PAI-1 is present under the cells in the ECM 
and that it is accessible to solution-phase t-PA. Immunogold 
electron microscopy revealed that <1% of  the PAI-1 was pres- 
ent on the dorsal cell surface of these cells. 
Materials and Methods 
Reagents 
Reagents were obtained as follows: FCS, trypsin, penicillin, and streptomy- 
cin from Gibco Laboratories (Grand Island,  NY);  medium  199  (M199) 
from M. A. Bioproducts (Bethesda, MD); tissue culture plasticware from 
Coming Science Products (Coming, NY); endothelial cell growth factor 
from Biomedical Technologies, Inc. (Stoughton, MA); methionine-free  me- 
dia from Irvine Scientific (Irvine, CA); BSA, ovalbumin, chymotrypsino- 
gen, phosphorylase b, ~-galactosidase, Triton X-100, Tris base, casein, por- 
cine intestinal beparin, purified goat IgG, and EDTA from Sigma Chemical 
Co. (St. Louis, MO); Con A-Sepharose and lysine-Sepharose from Phar= 
macia LKB Biotechnology Inc. (Piseataway,  N J); glycine and XAR x-ray 
film from Eastman Kodak Co. (Rochester, NY); aprotinin (Trasylol) and bo- 
vine fibrinogen from Caihiochem-Behring Corp. (La Joila, CA); affinity- 
purified goat anti-rabbit IgG from Miles Laboratories Inc. (Naperville, IL); 
Tween 80 from J. T. Baker Chemical Co.  (Phillipsberg, NJ); carrier-free 
Na  125I from  Amersham Corp.  (Arlington  Heights,  IL);  nitrocellulose 
sheets from Schleicher & Schuell, Inc. (Keene, NH); purified fibronectin 
from Meloy Laboratories Inc.  (Springfield, VA);  solid-state lactoperoxi- 
dase-glucose oxidase and reagents for SDS-PAGE from Bio-Rad Laborato- 
ries (Richmond, CA). 
Fibrinolytic Proteins 
t-PA was purified from human melanoma cell-conditioned medium, and its 
activity was determined by the ~25I-fibrin plate assay as described previ- 
ously (Schleef et al.,  1985).  The final product had a  specific activity of 
,x,500,000 U/mg of  protein when compared with the t-PA International Stan- 
dard and consisted primarily (>90%) of the single-chain form. The t-PA 
International Standard (83/517)  and the urokinase International Standard 
(66/46)  were kindly supplied by the National Institute for Biological Stan- 
dards and Controls (London, Great Britain). Goat antiserum to t-PA was 
obtained from Bio-Pool (Hornefors, Sweden), and the immunoglobulin G 
fraction was prepared as described previously (Schleef et ai.,  1985). 
Human PAId was purified from the media conditioned by a transformed 
human lung fibroblast cell line (SVdo WI38 VAI3 2RA) according to proce- 
dures described previously (Hekman and Loskutoff, 1988).  PAId was iso- 
lated primarily in a latent form and was activated by treatment with 4  M 
guanidine-hydrochloride  (1 h, 37°C) followed by dialysis against PBS at 4°C 
(Hekman and Loskutoff,  1985,  1988).  PAId activity was quantitated by 
measuring its ability to inhibit t-PA  mediated lysis of ~25I-labeled fibrin 
(Schleef et al.,  1988b).  1 U of PAId is defined as the amount required to 
inhibit the activity of 2 IU of t-PA by 50%. Antiserum to purified PAI-1 was 
raised in both New Zealand rabbits and White Lewis rats (Breeding Colony, 
Research Institute of Scripps Clinic) according to standard procedures. Rab- 
bit antibodies to PAId were affinity purified using human PAId bound to 
cyanogen bromide-activated Sepharose 4B. 
Growth and Treatment of  HUVECs 
HUVECs were isolated from 2-5 freshly collected umbilical cords, pooled, 
and grown in culture dishes coated with purified fibronectin (1  #g/cm2). 
The  growth medium consisted of M199  with 20%  FCS,  and  was sup- 
plemented with endothelial cell growth factor (ECGF; 75 #g/ml), porcine 
intestinal beparin (90 #g/ml), and antibiotics (Schleef et al.,  1988a).  For 
experimental use, HUVECs were grown to confluency in 24-well Costar 
culture plates (Corning Science Products) and maintained at confluency for 
3 d before use. To prepare conditioned media (CM), the monolayers were 
washed with 0.5 ml of serum-free M199 and then incubaaxl in the presence 
or absence of t-PA (0-10 #g/ml) for up to 8 h in M199. The CM was cen- 
trifuged (10,000 g,  10 min, 4°C) and stored at  -20°C until  used. Cell ly- 
sates were prepared by washing the monolayers with cold PBS (0.01 M 
sodium phosphate, 0.14 M NaCI, pH 7.4) and extracting the cellular com- 
ponents for  10 min at 37°C with 0.5  ml of PBS containing 0.5%  Triton 
X-100. The lysates were removed and stored at -20°C until used. ECM was 
prepared by washing Triton X-100 extracted plates three times with distilled 
water to remove remaining cellular components. Light microscopic exami- 
nation for the presence of cellular debris indicated that this extraction proce- 
dure completely removed visible cellular components from the culture dishes 
(Mimuro et al.,  1987).  ECM bound to the culture dishes was solubilized 
by the addition of 0.5  ml of SDS sample buffer. 
Immunoradiometric Assays (IRMAs) 
t-PA/PAI-1 complexes were measured in a two-site IRMA as described pre- 
viously (Mimuro et al., 1987; Hekman and Loskutoff, 1988).  Briefly, sam- 
ples were diluted in IRMA buffer (PBS supplemented with 3% BSA, 5 mM 
EDTA,  0.1% Tween 80, and 0.02%  NAN3) and incubated for 1.5 h at 37°C 
in microtiter wells precoated with goat anti-t-PA (50 #l/well,  l0 #g/ml). 
Plates were blocked with 3% BSA and after each incubation step, washed 
with PBS containing 0.1% BSA, 0.05%  NAN3, and 0.05% Tween 80. Bound 
PAId was quantitated radiometrically after incubating the washed wells first 
with rabbit anti-PAl-I, and then with tESl-labeled goat anti-rabbit IgG (105 
cpm/well). The wells were individually removed, and the radioactivity in 
each was determined. PAId antigen was quantitated by a similar two-site 
IRMA. In this case, affinity-purified  rabbit antibodies to human PAId (5 #g/ 
ml in PBS) were coated onto microtiter wells (4°C for 16 h). After blocking 
the wells with 3% BSA and washing, test samples or purified PAl-I, diluted 
in IRMA buffer,  were incubated in the antibody-coated wells at 37°C for 
1.5 h. Bound PAL1 was quantitated  radiometrically  by incubating the washed 
wells first with rat antiserum to human PALl  and then with  1251-labeled 
goat anti-rat IgG. 
Quantitation of  ECM-associated PAl4 
PAId antigen associated with the Triton Xd00-insoluble ECM was quanti- 
tared immunologically either directly on the plate (Mimuro et al., 1987) or 
by solubilizing the ECM into SDS sample buffer and analyzing the samples 
by immunoblotting (described below). To quantitate ECM PAId directly on 
96-well microtiter plates, the ECM were incubated (4°C,  I h) with M199 
supplemented with 5  mg/ml normal goat IgG (MI99-IgG) to block non- 
specific IgG binding sites. The wells were then incubated (1 h, 37°C) with 
a primary antibody (10/zg/ml of either affinity-purified rabbit anti-PAid or 
of normal rabbit IgG) diluted in M199-IgG.  The plates were washed and the 
bound antibodies were detected with  t25I-goat anti-rabbit IgG (2  x  105 
cpm/100 #1). After washing the wells with M199, the ECM was solubilized 
into SDS sample buffer and the radioactivity in each well was determined 
in a gamma counter. 
Immunoblotting 
The relative molecular mass species of PAI-1 amigen in the various samples 
was assessed by immunoblotting as described previously (Schleef et al., 
1988a).  Samples were first subjected to discontinuous SDS-PAGE (Laem- 
mli, 1970), and then the proteins were electrophoretically transferred (50 V, 
1.5 h) to nitrocellulose using a buffer containing 50 mM Tris base, 95 mM 
glycine, 20% methanol, and 0.01% SDS (Towbin et al., 1979). The nitrocel- 
lulose sheets were soaked in PBS containing 1% casein (PBS/casein) for 1 h 
at room temperature to block additional protein binding sites and then were 
incubated overnight at 4°C in PBS/casein containing rabbit antiserum to hu- 
man PAId  (1:500  dilution). The nitrocellulose sheets were washed three 
times (10 min each wash) with PBS/easein and then incubated for 2 h at 
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After washing, the nitrocellulose sheets were dried and exposed to XAR 
x-ray film for 24-48 h at  -70"C. 
Immunoelectron Microscopy 
HUVEC monolayers in 24-well Costar plates were incubated (4°C, I h) with 
MI99-IgG to block nonspecific IgG binding sites. The cells were then in- 
cubated (1 h, 4°C) with a primary antibody (10 #g/ml of either affinity- 
purified rabbit anti-PAI-1  or normal rabbit lgG) diluted in MI99-IgG. The 
cells  were washed and  incubated  (4°C,  1 h)  with  10-mm-diam gold- 
conjugated goat anti-rabbit IgG (Janssen Life Sciences Products, Piscata- 
way, NJ) diluted in MI99-IgG. After washing the monolayers with M199, 
the cells were stored in cold Karnovsky's fixation buffer (1.5% glutaralde- 
hyde, 2%  paraformaldehyde in 0.1  M  cacodylate buffer, pH  7.4) until 
processed.  The cells were briefly rinsed with PBS, postfixed with  1.5% 
OsO4 in 0.1 M cacodylate buffer, pH 7.2, for 1 h at room temperature, and 
dehydrated in a graded ethanol series. The wells were flat embedded in Epon 
812 and after polymerization, stained en block with uranyl acetate. 
To quantify the amount of anti-PAI-1  specific gold particles bound to the 
cell surface or culture substratum, four strips of 3 x  8 mm from each group 
were cut out from the Epon sheet containing cell monolayers. Two such 
strips from the same group were sandwiched together, cells apposed, with 
fresh Epon. Sections from these sandwiched blocks bearing two layers of 
cells were cut perpendicular to the culture substratum, double stained with 
uranyl acetate and lead citrate, and mounted on 100-mesh parallel lined 
grids (Ted Pelta, Inc., Tustin, CA) so that both cell layers ran longitudinally 
between two grid bars. Quantification of gold particles on nucleated cells 
was carried out at 15,000x on a Hitachi 12-UA electron microscope. Only 
one section from each block was used for quantitative analysis. A total of 
eight blocks containing 16 different areas of cells was examined in each 
group. The density of gold markers is expressed as the number of particles 
per 25 nucleated cells from a representative section. 
Miscellaneous 
protein concentration was determined by the method of Bradford (1976). 
Antibodies were enzymatically labeled with t25I by using solid-state lacto- 
peroxidase-glucose oxidase reagents and carrier-free Na 1251. The 12~I-la- 
beled goat anti-rabbit IgG had a specific activity of 2-5  ×  106 cpm/tzg 
protein. 
did not affect HUVEC morphology or viability as indicated 
by  staining with  trypan blue.  Furthermore,  incubation of 
HUVEC monolayers with t-PA diluted in either serum-free 
media supplemented with 1% BSA/ECGF/heparin or in 20% 
Results 
Effect of t-PA on the Distribution 
of PAI-1 in HUVECs 
The  interactions between exogenously added  t-PA and en- 
dogenous PAI-1 associated with intact HUVEC monolayers 
were initially assessed by irnmunoblotting analysis. As sev- 
eral other investigators have reported (Kooistra et al.,  1986; 
Barnathan et al.,  1988; Sakata et al.,  1988), the addition of 
t-PA  to  HUVECs  in  vitro  resulted  in  the  formation  of 
t-PA/PAI-1  complexes  of  100,000 Mr  in the  CM,  and of a 
cleaved or modified form of PAI-1 of 42,000 M, (Fig.  1, A). 
Neither  the  size  nor the  relative amount of PAI-1  antigen 
present in cell lysates (i.e.,  the Triton X-100-soluble frac- 
tion) of HUVECs was affected by t-PA treatment (Fig.  1 B). 
In contrast,  t-PA caused  a  dose-dependent decrease  in the 
PAI-1 content of the Triton X-100-insoluble ECM (Fig. 1 C). 
Approximately 10-20% of the total PAI-1 remained associated 
with the ECM even at the highest t-PA concentrations. This 
PAI-1 appeared to be resistant to t-PA since neither modified 
PAI-1  nor  t-PA/PAI-1  complexes  could  be  detected  in the 
ECM by immunoblotting. Phase-contrast microscopic exami- 
nation indicated that  the  HUVEC  monolayers exhibited a 
normal  cobblestone  morphology  in  serum-free  conditions 
for short periods of incubation, t-PA-treatment (<10 #g/ml) 
Figure 1.  Immunoblotting analysis for PAI-I in HUVECs treated 
with t-PA.  Confluent monolayers were  incubated (1  h,  37°C)  in 
serum-free media supplemented with the indicated concentrations 
of t-PA (lane 1, 0; lane 2, 0.01 #g/ml; lane 3, 0.1 #tg/ml; lane 4, 1 #g/ 
ml; lane 5, 2 #g/ml, lane 6, 10/~g/ml). The CM were removed and 
the cells were lysed with 0.25% Triton X-100.  After washing, the 
Triton X-100-insoluble ECM  remaining on the plate was solubi- 
lized in SDS sample buffer. Samples (100 #1 aliquots corrrespond- 
ing to 4  ×  104 cells) of CM  (A), cell lysates (B), and ECM (C) 
were fractionated by SDS-PAGE, electrophoretically transferred to 
nitrocellulose, and analyzed by immunoblotting using rabbit anti- 
PAI-1 followed by J25I-goat anti-rabbit IgG. The results show the 
dried nitrocellulose sheets exposed to XAR x-ray film for 48 h. Po- 
sitions of relative molecular mass standards are indicated. 
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HUVECs with Triton X-100 or EDTA. Confluent monolayers were 
incubated with media alone  (lanes I  and 2) or with media  sup- 
plemented with 10 #g/ml t-PA (lanes 3 and 4). After  l h at 37°C, 
the monolayers were washed and ECM were prepared  either  by 
removing the cells by lysis with 0.25% Triton X-100 (lanes 1 and 
3) or by detaching the cells with  l0 mM EDTA (lanes 2 and 4). 
The resulting ECM preparations were washed three times with dis- 
tilled water and extracted into SDS sample buffer. Samples (100 #l 
aliquots corresponding to 4  x  104 cells) were fractionated by SDS- 
PAGE, electrophoretically  transferred  to nitrocellulose,  and ana- 
lyzed with rabbit anti-PAid followed by 125I-goat anti-rabbit IgG. 
The dried nitrocellulose was exposed to XAR x-ray film for 24 h. 
Positions of relative molecular mass standards are indicated. 
serum-containing growth media supplemented with 2  U/ml 
Trasylol resulted in t-PA/PAI-1 complex formation and deple- 
tion of PAI-1 from the ECM comparable to the data in Fig. 
1 (data not shown). 
A number of intracellular proteins are known to remain as- 
sociated with the ECM after the extraction of cultured cells 
with detergents (Avnur and Geiger,  1981; Carter and Hako- 
mori,  1981). To determine whether Triton X-100-insoluble 
intracellular proteins were the source of ECM PAId, we also 
prepared ECM by removing the ceils intact with the divalent 
cation chelator,  EDTA.  Fig.  2  demonstrates that approxi- 
mately equivalent amounts of PAI-I were present in ECM 
prepared by either Triton X-100 treatment (Fig.  2,  lane 1) 
or by detaching the cells intact with EDTA (lane 2). Further- 
more, treatment of HUVEC monolayers with t-PA (10 #g/ml) 
removes the majority of the PAI-1 present in the ECM, inde- 
pendent of whether the cells were subsequently removed by 
treatment with Triton X-100 (Fig. 2, lane 3) or with EDTA 
(lane 4). 
To quantitate  the  amount of complexes that  are  formed 
during  the  interaction  of t-PA  with  HUVECs,  a  two-site 
IRMA was used. Control HUVECs secrete t-PA at a constant 
rate of "00.25 ng/h per  llY cells and this t-PA forms com- 
plexes with endogenously released PAId (Fig. 3 A). In con- 
trast to these results,  when exogenous t-PA is added to the 
cultures, there is an initial rapid rate of complex formation 
which is then followed by a slower more linear second phase 
(Fig. 3 A). Analysis of these samples in a two-site IRMA for 
PAI-1 antigen (Fig. 3 B) revealed a corresponding rapid, t-PA 
mediated  increase  in  the  inhibitor,  followed by  a  second 
slower rate of PAI-1 accumulation. The initial rapid increase 
is again in contrast to the slower, relatively constant linear 
release of PAI-1 into the CM of untreated HUVECs which 
occurs at ,08  ng/h per  1@ cells. 
Ultrastructural Localization of  PAI-1 
Immunoelectron  microscopy  was  used  to  more  precisely 
localize  the  PAI-1  that  is  associated  with  intact  HUVEC 
monolayers and is accessible to exogenous t-PA.  Analysis of 
cross sections of nonpermeabilized  HUVECs  stained  first 
with rabbit antibodies to PAId and then with gold-conjugated 
goat anti-rabbit IgG revealed the presence of PAI-1 antigen 
primarily between the culture substratum and the underlying 
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Figure 3. Influence of exogenous 
t-PA on  the  rate  of t-PA/PAI-1 
complex formation and PAI-I an- 
tigen accumulation  in the media 
conditioned  by HUVECs.  Con- 
fluent HUVECs were  incubated 
at 37°C in media alone (o) or in 
media  supplemented  with  1 #g/ 
ml t-PA (e).  The resulting  CM 
were  collected  at  the  indicated 
times and analyzed for t-PA/PAI-I 
complexes (A) and PAId antigen 
(B)  by  two-site  IRMAs  as  de- 
scribed in Materials and Methods. 
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Particles Associated with HUVEC Monolayers 
Immunogold particles  per 25 
cell lengths 
Dorsal  Ventral  surface/ 
Pretreatment  Primary antibody  surface  culture substratum 
M199  Rabbit anti-PAI- 1  13  1,706 
t-PA  in M199  Rabbit anti-PAI-1  7  485 
M199  Nonimmune rabbit IgG  6  19 
Confluent  HUVEC  monolayers  were  incubated (1  h,  370C) in M199 in the 
presence or absence of 5 ~g/ml  t-PA.  The cells were washed and incubated 
(1  h,  4°C) with  10  /zg/ml of affinity-purified rabbit  antibodies to PAI-I or 
nonimmune rabbit lgG followed by gold-conjugated goat anti-rabbit  lgG. The 
cells  were  fixed and processed  for transmission  electron  microscopy  as de- 
scribed in Materials and Methods.  Data shown are from a representative  sec- 
tion and expressed as the total number of immunogold particles detected on the 
dorsal  and  ventral  cell surfaces  of 25  cells  displaying  nuclei,  representing 
800-1,000  ~M of linear culture  substratum surface. 
ventral cell membrane (Fig. 4 A). Quantitation of the total 
gold particles distributed over 25 nucleated cell lengths (,x,800- 
1,000 #M linear length) confirmed the presence of PAI-1 be- 
neath the ventral cell surface (Table I), and demonstrated that 
<1% of the total gold particles were present on the dorsal cell 
surface membrane. Incubation of HUVECs with t-PA (5/~g/ 
ml; 1 h, 37°C) before immunoelectron microscopic localiza- 
tion of PAI-1 significantly decreased the number of gold par- 
ticles detected both beneath the monolayers (Fig. 4 B; Table 
I), and on the dorsal cell surface (Table I). In control experi- 
ments, few gold particles were detected in cross sections of 
HUVECs that were incubated with normal rabbit IgG fol- 
lowed by gold-conjugated goat anti-rabbit IgG (Fig. 4 C; Ta- 
ble I). 
Kinetics of the Interaction between t-PA and 
ECM-associated PAI-I 
The above observations indicate that the majority of HUVEC- 
associated PAI-1 is present in the ECM. Moreover, the PAI-1 
in the ECM beneath HUVEC monolayers appears to be ac- 
cessible to solution-phase t-PA.  Kinetic experiments were 
performed in the presence or absence of the cell monolayer 
to further investigate the influence of the cells on the accessi- 
bility of this population of PAI-1. If the monolayers were first 
removed, the t-PA-mediated decreases in ECM PAI-1 were 
quite rapid (Fig. 5), with >70% of the PAI-1 in the ECM be- 
ing removed within 15 min with 1 #g/ml of t-PA.  Immuno- 
blotting analysis of the supernatants from the t-PA-treated 
ECM revealed the presence of t-PA/PAI-1 complexes and of 
degraded PAI-1 (data not shown) similar to the PAI-1 profile 
obtained by t-PA  treatment of intact HUVEC  monolayers 
(Fig. 1 A). The rate of PAI-1 removal from the ECM was con- 
siderably slower in the presence of cells. For example, 1 #g/ 
ml t-PA removed only 25 % of the PAI-1 from the ECM be- 
neath HUVEC monolayers within 15 min, and took ,x,75 min 
to remove 70 % of it. Treatment of HUVEC monolayers with 
low concentrations of t-PA  (0.25/zg/ml) only partially de- 
pleted PAI-1 from beneath the monolayers. 
Effect of t-PA on the Production of  PAl-1 
by HUVECs 
The production of PAI-1 is regulated by a wide variety ofbio- 
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Figure 5. Influence of the cell monolayer on the rate of interaction 
between exogenous t-PA and PAI-I in the ECM.  Intact HUVEC 
monolayers (open symbols) or ECM preparations (solid symbols) 
were incubated with 0.25 (o, e), 1 (t2, I), or 5 (,x, A) #g/ml t-PA 
in serum-free media. At the indicated times, the plates were washed 
and the monolayers were lysed with 0.5% Triton X-100. PAI-I as- 
sociated with the ECM was then quantitated by incubation (1 h, 
37°C) with affinity-purified rabbit antibodies to PAI-I followed by 
~25I-goat anti-rabbit IgG. Data points represent the average of dup- 
licates and are expressed as a percentage of control samples in- 
cubated in serum-free media in the absence of t-PA. 
logically important compounds and conditions (Loskutoff  et 
al.,  1988). Experiments were therefore performed to deter- 
mine if the t-PA treatment itself and/or the depletion of PAI-1 
from the ECM alters the rate of PAI-1 production. HUVECs 
were treated with t-PA for 2 h to remove PAI-1 from the ECM 
and then were incubated in the presence of [35S]methionine 
for various times. Analysis of the resulting samples by SDS- 
PAGE and autoradiography failed to demonstrate significant 
differences in the amount of PAI-1 deposited into the ECM 
of control and t-PA-treated HUVECs (Fig. 6). Immnnopre- 
cipitation of the 35S-labeled PAIl present in the cell lysates or 
accumulating  in the CM over this time period, confirmed these 
results (data not shown). Thus, t-PA treatment of HUVECs 
did not affect the subsequent rate of PAI-1 production. 
Discussion 
Biochemical studies  of ECM  prepared by  standard  tech- 
niques using nonionic or zwitterionic detergents demonstrate 
that PAI-1 is associated with the ECM from a variety of cul- 
tured cells. However, the extraction of cells with detergents 
results in an ECM preparation that may also contain a num- 
ber of insoluble cellular components (Avnur and  Geiger, 
1981; Carter and  Hakomori,  1981).  These considerations 
raise the possibility that PAI-I is not an integral component 
of the ECM, but rather a contaminating cellular component 
associated with insoluble surface or cytoskeletal elements. In 
this report, we have used procedures that do not suffer from 
this problem to study PAI-1 in the ECM of HUVECs.  For 
example, the ceils were removed intact from the underlying 
ECM by incubation with the divalent cation chelator, EDTA. 
Similar quantities of  PAI-1 were detected in these ECM prep- 
arations and in ECM prepared by removing HUVECs by ly- 
sis with Triton X-100 (Fig. 2), suggesting that PAI-1 is actu- 
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ization  of  PAI-I  in  intact  nonpermeabilized 
HUVECs. HUVEC monolayers in 24-well Cos- 
tar plates were incubated (1 h, 37°C) in serum- 
free media either in the absence (A and C) or 
presence  (B) of 10 #g/ml t-PA. The cultures 
were washed, blocked with MI99-IgG, and in- 
cubated  (1  h,  37°C)  with  10 #g/ml of either 
affinity-purified  rabbit antibodies to PAI-I (A 
and B) or normal rabbit immunoglobulins  (C) 
in  MI99-IgG.  Washed  cells  were  incubated 
(4°C,  1 h) with gold-conjugated goat anti-rab- 
bit IgG and then processed for electron micros- 
copy as described  in Materials  and Methods. 
N,  nucleus; arrowheads,  immunogold parti- 
cles. (A, inset) Low magnification (2,000×) of 
HUVEC  with  arrow  indicating  approximate 
area enlarged  in A. Bars, 250 nm. 
The Journal of Cell Biology, Volume 110, 1990  160 Figure  6.  Effect of t-PA-pretreatment on the deposition of [3sS]- 
methionine-labeled proteins into HUVEC ECM.  HUVECs were 
incubated (2 h, 37°C) in the absence (lanes 1, 3, and 5) or presence 
(lanes 2, 4, and 6) of 1/zg/ml t-PA. The monolayers were washed 
and incubated with [35S]methionine  for 1 (lanes 1 and 2), 2 (lanes 
3 and 4), or 4 h (lanes 5 and 6) at 37°C. The cells were lysed with 
0.25% Triton X-100 and the insoluble ECM extracted into SDS 
sample buffer. Aliquots (100 #1) of  the ECM were subjected to SDS- 
PAGE followed by autoradiography. Positions of relative molecular 
mass standards are indicated. 
ally present in the ECM and not a  contaminating cellular 
component. This conclusion is supported by additional  studies 
in which immunoelectron microscopy was used to localize 
PAI-1  in endothelial cells (Fig.  4;  Table I).  These studies 
demonstrate the presence of considerable PAl-l-specific im- 
munogold particles on the cell substratum  underlying the 
ventral cell surface of intact (nonpermeabilized) monolayers. 
Staining was prominent at the cell periphery suggesting that 
the primary and gold-conjugated secondary antibodies were 
able to penetrate between the regions of cell-cell contact and 
then bind to PAl-1 present in the ECM beneath HUVECs. 
Taken together, these results demonstrate that PAI-1 is pres- 
ent in the ECM of these cells. Recent observations suggest 
that it is bound, at least in part, to vitronectin also present 
in the ECM (Mimuro and Loskutoff, 1989a,b). The signifi- 
cance of this association remains to be determined. 
Previous studies have suggested that PAl-1 is also present 
on the surface of the plasma membrane of HUVECs (Sakata 
et al.,  1988; Barnathan et al.,  1988). This conclusion was 
based on the observations that the binding of t-PA to a high- 
affinity binding site on HUVECs (a) required the catalytic 
site of t-PA, (b) was inhibited by antibodies to PAl-I, and (c) 
formed immunoprecipitable complexes with PAId associated 
with radioiodinated HUVECs (Barnathan et al.,  1988). Our 
data suggest that it is the PAI-1 located in the ECM beneath 
cultured HUVECs, and not on the cell surface, that may ac- 
tually comprise this high-affinity binding site for t-PA (Haj- 
jar et al.,  1987;  Barnathan et al.,  1988). For example, the 
PAI-1 in the ECM of  confluent monolayers is clearly accessi- 
ble to exogenously added tPA (Figs.  1, 2, and 4;  Table I). 
Moreover, the immunoelectron microscope studies (Fig. 4; 
Table I) revealed that very little PAI-1 was actually present 
on the dorsal cell surface (<1% of the total detectable PAl-l). 
The ECM-associated  PAI-1 readily forms complexes with 
exogenous t-PA  (Fig.  l)  and  these  complexes are  rapidly 
released into the medium when the cells are incubated at 
37°C (Fig. 1). This behavior is similar to the behavior of the 
t-PA/PAI-1 complexes described in the previous studies (Bar- 
nathan et al.,  1988). Thus, based on the available informa- 
tion, it would seem that the majority of exogenously added 
tPA binds to PAI-1 in the ECM and not on the cell surface. 
Additional studies are needed to delineate the significance of 
the small amount of PAI-1 actually detected on the surface 
(Table I). 
Kinetic analysis of the t-PA-mediated decreases in ECM- 
associated PAI-1 suggest that cultured HUVEC monolayers 
retard, but do not completely exclude, the access of various 
exogenous proteins to the culture substratum.  The almost 
complete accessibility of solution-phase t-PA for PAI-1 in the 
ECM is not surprising, since the junctional relationships of 
in situ endothelium may not be preserved in vitro. In fact, 
these relationships may change dramatically in cultured cells 
since the passage of macromolecules tracers between cells 
is dependent on a variety of factors (Furie et al.,  1984; Del 
Vicchio et al.,  1987; Huang et al.,  1988) including the cul- 
ture substratum used for the growth of  the cells. Thus, bovine 
microvascular endothelial cells grown on gelatin do not form 
intracellular  junctions impenetrable to macromolecular trac- 
ers (i.e., tight junctions). However, when grown on a com- 
plex basement membrane (e.g., human amnion) relatively 
impenetrable intracellular junctions are formed similar to 
those present in  intact blood vessels (Furie et al.,  1984). 
Thus, our results suggest that HUVECs grown on fibronec- 
tin-coated plastic may also lack tight junctions, a possibility 
that may contribute to the current confusion in the literature 
concerning the cellular location of PAl-1 (i.e.,  surface vs. 
ECM).  It should be noted that other pathways of transport 
also may exist in endothelial cells (e.g., vesicles) and con- 
tribute to the accessibility of solution-phase t-PA for ECM 
PAI-1. In addition, the inability of low concentrations of t-PA 
(e.g., 0.25 #g/ml; Fig.  5) to efficiently deplete PAI-I  from 
beneath the monolayers may result from the ongoing deposi- 
tion of newly synthesized PAI-1 by the HUVECs. 
Although the majority of ECM PAI-1 interacts with solu- 
tion-phase t-PA, a variable proportion (e.g.,  10-20%) was 
found to be non-reactive and remained associated with the 
ECM.  Similar quantities of t-PA-resistant PAI-1 also were 
detected in isolated ECM preparations (Fig.  5) suggesting 
that the cells themselves do not interfere with this interac- 
tion. Latent PAl-1 is not cleaved by t-PA (Hekman and Los- 
kutoff, 1985;  Erickson et al.,  1986), nor does it form com- 
plexes with it (Hekman and Loskutoff, 1985; Erickson et al., 
1986),  suggesting that the resistant PAI-1 may represent a 
small amount of the inactive inhibitor. Alternatively, the re- 
sistant inhibitor may be sterically inaccessible to solution- 
phase t-PA. 
Endothelial cells in vivo may be exposed to a wide range 
of t-PA concentrations. For example, the level of t-PA in hu- 
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(Juhan-Vague et al.,  1988;  Prowse and MacGregor,  1988), 
but may increase threefold after physical exercise, venous oc- 
clusion, or infusion of 1-deamino-8-D-arginine  (Juhan-Vague 
et al.,  1988;  Prowse and MacGregor,  1988).  Furthermore, 
the recent use of recombinant t-PA for thrombolytic therapy 
can result in a transient  increase in plasma t-PA levels to 
)1/zg/ml (Loscalzo and Braunwald,  1988; Lucore and Sobel, 
1988;  Sobel,  1988).  Whether PAI-1 is present in the ECM 
of endothelium in vivo and is affected by such alterations  in 
the plasma level of t-PA remains to be determined. 
Infusion of t-PA during  thrombolytic therapy  frequently 
results  in a  rapid  increase  in circulating  t-PA/PAI-1  com- 
plexes (Lucore and Sorbel, 1988), and a small number of pa- 
tients  demonstrate  increased  plasma  PAI-1 activity  within 
8-24 h after infusion with therapeutic  doses of t-PA (Lucore 
and Sorbel,  1988).  The inability to demonstrate increased 
PAI-1 synthesis by cultured  HUVECs  after t-PA treatment 
(Fig. 6), suggests that t-PA infusion does not directly stimu- 
late the production of PAI-1 by endothelial cells. It should be 
noted, however,  that PAI-1 gene expression is induced by a 
wide variety  of substances (e.g., cytokines released by acti- 
vated leukocytes, transforming  growth factor ~  released by 
platelets, etc.) (Loskutoff et al., 1988). Thus, increased PAI- 
l  production  in these  patients  may  be  mediated  by  com- 
pounds released from cellular elements of the thrombus itself 
during  its' degradation. 
In addition to PAI-1, the ECM of endothelial cell binds sev- 
eral other proteins involved in blood coagulation and fibrino- 
lysis, including plasminogen (Knudsen  et al.,  1986),  fibro- 
nectin (Jaffe et al., 1976), and yon Willebrand factor (Hormia 
et al.,  1983).  When the endothelial cell lining is disrupted, 
blood coagulation is initiated  and a fibrin clot is formed in 
association with the subendothelial matrix. The location of 
active PAI-1 in the ECM may play a critical role in protecting 
the ECM and the ECM-associated fibrin from PA-mediated 
degradation  through  its specific inactivation  of PAs. In this 
regard,  Knudsen  and  Nachman  (1988)  demonstrated  that 
PAI-1 associated with HUVEC ECM prevents  plasmin for- 
mation and inhibits  degradation  of ECM  preparations  that 
are incubated with plasminogen and the t-PA secreting Bowes 
melanoma cell line. Thus, PAI-1 in the ECM may influence 
a variety of biologic events, including hemostasis, tumor in- 
vasion,  and cell migration. 
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